We are live on ! Find out more
Prosight Management

Prosight Management Portfolio holdings

AUM $515M Turnover 48.89%
1-Year Est. Return 2.95%
This Fund
S&P 500
This Quarter Est. Return
-19.33%
1 Year Est. Return
-2.95%
3 Year Est. Return
+53.41%
5 Year Est. Return
-10.05%
10 Year Est. Return
–
AUM
$335M
AUM Growth
-$24.9M
Cap. Flow
+$60.4M
Cap. Flow %
18.05%
Top 10 Hldgs %
58.78%
Holding
55
New
11
Increased
22
Reduced
13
Closed
9
Avg Time Held
0.9 years
Top 10 Avg Time Held
0.7 years
Top 20 Avg Time Held
0.6 years

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$12.3M
2
GH icon
Guardant Health
GH
+$9.7M
3
KURA icon
Kura Oncology
KURA
+$6.79M
4
KIDS icon
OrthoPediatrics
KIDS
+$6.68M
5
PFE icon
Pfizer
PFE
+$5.97M

Sector Composition

Rank Sector Weight
1 Healthcare 95.26%
2 Industrials 4.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
LKFT icon
1
Lakefront Biotherapeutics American Depositary Shares
LKFT
$2.25B
$33.5M 10%
1,349,980
+418,468
+45% +$11.9M
2021 Q1
13 quarters
ADCT icon
2
ADC Therapeutics
ADCT
$193M
$30.2M 9.04%
9,570,000
+2,519,700
+36% +$10M
2022 Q3
7 quarters
ROIV icon
3
Roivant Sciences
ROIV
$28.1B
$21.1M 6.32%
2,000,000
+140,000
+8% +$1.53M
2024 Q1
1 quarter
BBIO icon
4
BridgeBio Pharma
BBIO
$15.2B
$20.3M 6.06%
800,000
+210,470
+36% +$5.75M
2024 Q1
1 quarter
ZBH icon
5
Zimmer Biomet
ZBH
$19.6B
$18.5M 5.51%
170,000
+151,092
+799% +$17.8M
2024 Q1
1 quarter
MGTX icon
6
MeiraGTx Holdings
MGTX
$813M
$18.3M 5.48%
4,352,700
+335,399
+8% +$1.69M
2022 Q1
9 quarters
STTK icon
7
Shattuck Labs
STTK
$455M
$18M 5.39%
4,670,000
+945,000
+25% +$7.68M
2021 Q3
11 quarters
KURA icon
8
Kura Oncology
KURA
$674M
$13M 3.88%
629,900
-330,100
-34% -$6.79M
2023 Q2
4 quarters
CYTK icon
9
Cytokinetics
CYTK
$7.15B
$12.5M 3.72%
230,000
-15,000
-6% -$905K
2024 Q1
1 quarter
SNDX icon
10
Syndax Pharmaceuticals
SNDX
$771M
$11.3M 3.38%
+551,544
New +$11.5M
2024 Q2
0 quarters
MIRM icon
11
Mirum Pharmaceuticals
MIRM
$6.04B
$10.8M 3.22%
314,800
-150,200
-32% -$3.94M
2022 Q1
9 quarters
KELYA icon
12
Kelly Services Class A
KELYA
$462M
$10.5M 3.15%
492,340
+143,654
+41% +$3.26M
2024 Q1
1 quarter
ZYME icon
13
Zymeworks
ZYME
$1.83B
$10M 3%
1,180,000
+769,052
+187% +$6.85M
2024 Q1
1 quarter
IMVT icon
14
Immunovant
IMVT
$6.86B
$8.58M 2.56%
325,000
+130,000
+67% +$3.7M
2024 Q1
1 quarter
SDGR icon
15
Schrodinger
SDGR
$2.04B
$7.14M 2.13%
+369,261
New +$8.51M
2024 Q2
0 quarters
ABCL icon
16
AbCellera Biologics
ABCL
$3.6B
$6.96M 2.08%
2,352,633
+562,633
+31% +$2.13M
2022 Q3
7 quarters
ALKS icon
17
Alkermes
ALKS
$7.87B
$6.63M 1.98%
275,000
+60,000
+28% +$1.47M
2022 Q3
7 quarters
ERAS icon
18
Erasca
ERAS
$4.83B
$6.49M 1.94%
2,750,000
-909,755
-25% -$1.96M
2023 Q1
5 quarters
VKTX icon
19
Viking Therapeutics
VKTX
$3.34B
$6.1M 1.82%
115,000
+75,954
+195% +$4.98M
2024 Q1
1 quarter
PRTA icon
20
Prothena
PRTA
$429M
$5.92M 1.77%
286,926
+116,457
+68% +$2.52M
2020 Q3
15 quarters
KIDS icon
21
OrthoPediatrics
KIDS
$826M
$5.76M 1.72%
200,216
-218,045
-52% -$6.68M
2023 Q4
2 quarters
OPCH icon
22
Option Care Health
OPCH
$4.75B
$5.68M 1.7%
205,000
+105,000
+105% +$3.13M
2022 Q4
6 quarters
DXCM icon
23
DexCom
DXCM
$30.8B
$5.59M 1.67%
49,317
+26,317
+114% +$3.33M
2023 Q3
3 quarters
ACCD icon
24
DELISTED
Accolade Inc
ACCD
$5.33M 1.59%
+1,489,525
New +$11.3M
2024 Q2
0 quarters
COGT icon
25
Cogent Biosciences
COGT
$4.84B
$4.22M 1.26%
500,000
-55,500
-10% -$421K
2024 Q1
1 quarter

Similar funds

Prosight Management's Q2 2024 Portfolio in Review

As of Q2 2024, Prosight Management held 55 positions worth $335M, down 6.9% from $359M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Prosight Management deployed $60.4M of net new capital in Q2 2024, opening 11 new positions and adding to 22 existing holdings. Its largest new stake was Syndax Pharmaceuticals: 551,544 shares worth $11.3M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 97% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Medtronic, an estimated $12.3M trimmed.

  • Prosight Management's largest Q2 2024 buy was Syndax Pharmaceuticals: 551,544 shares worth $11.3M.
  • Prosight Management added most to Zimmer Biomet in Q2 2024, an estimated $17.8M increase.
  • Prosight Management's biggest Q2 2024 reduction was Medtronic, cutting an estimated $12.3M.
  • Prosight Management fully exited Guardant Health in Q2 2024, selling an estimated $9.7M.
  • Prosight Management's ten largest holdings make up 59% of its $335M portfolio in Q2 2024.
  • Prosight Management opened 11 new positions and closed 9 in Q2 2024.
  • Prosight Management's portfolio value fell 6.9% quarter-over-quarter to $335M.

Based on Prosight Management's 13F filing for Q2 2024, filed 14 Aug 2024.